So many topics, so much to say
The role of forecasting in supporting strategic management decisions in oncology, post-marketing surveillance and other strategic management issues are going to be the areas on which I shall be focusing in this blog.
By on Dec 11, 2008The role of forecasting in supporting strategic management decisions in oncology, post-marketing surveillance and other strategic management issues are going to be the areas on which I shall be focusing in this blog.
To blog is one of those interesting experiences in life where one can spend a good deal of time considering a carefully constructed argument, prepare what one thinks is a nice piece, post it on the blog and then - nothing happens. Regardless of the doubt that always exists as to whether people are actually paying attention, care at all, or even consider the views worth reading, I shall be blogging here on issues relating to forecasting.
My particular interest at present is in the area of patient flow modeling. This comes from recent client demands as well as issues relating to changes in health policy in Europe and the USA where effective patient flow modeling is likely to play a major role. I'm referring specifically to two things - oncology and post-marketing surveillance.
The oncology market is the most complex and the most complicated sector in our industry. With products being used for multiple off-label indications, constantly changing scientific background, reimbursement issues that are boiling into a huge resource allocation dilemma, and companies pouring billions into R&D. I'll be commenting on this in some depth over the next few weeks.
Post-marketing surveillance is another area where things are changing a lot. The FDAAA last year specified that post-marketing surveillance using patient records is going to be a major part of FDA policy in the coming years. NICE and other similar organizations have specified the need for improved PMS tools. Where patient flow modeling fits into this is the ability of these models to support decision making where highly granular models of prescriber / patient behavior are required - and I'll be talking about this as well.
For now I bid myself and those of you who want to join in welcome to this new blog and hope that we shall be able to achieve that lofty goal of pushing hard against the status quo, reporting eagerly and accurately, and speaking truth to power.